Mechanism of Action
4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated K i values of 3nM and 13nM, respectively) with a dissociation half-life of greater…
Clinical Trials (5)
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
Loss of Exclusivity
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8821927 | Sep 18, 2029 | SubstanceProduct | — |